Baird Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $75

Benzinga · 11/25 21:21
Baird analyst Joel Beatty initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $75.